Sunesis acquires rights to Dainippon cancer compound
Executive Summary
Sunesis (fragment-based discovery) has licensed exclusive worldwide rights to develop and market Dainippon Pharmaceutical's preclinical oncology compound SPC-595.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice